Skip to content
PhageCocktails
Regulatory Pathway

How phage therapy is actually regulated

“Just get FDA approval” is not a step — it is a decade-long category problem. Here is the real map of how phage cocktails reach patients in 2026, in regulators’ own vocabulary: compassionate-use eINDs, the traditional IND→BLA path through CBER, Belgium’s magistral framework, and the European Pharmacopoeia’s new quality standard.

The jurisdiction matrix

RouteUnited StatesEurope
Single-patient compassionate use

How almost every patient is treated today.

Emergency IND / expanded access (21 CFR 312.310)National named-patient / Belgium magistral
Clinical trials

The path for AP-SA02, LBP-EC01, BX004.

Standard IND (CBER, Office of Vaccines)Clinical Trial Regulation; Ph. Eur. 5.31 quality
Market approval

No phage therapeutic has reached this yet.

Biologics License Application (BLA)Marketing Authorization (EMA)
Pharmacy compounding

Belgium’s framework is the world’s most workable.

Limited (503A/503B, not phage-tailored)Belgium magistral preparation (since 2018)

The US path

Phages are biologics under CBER. There is no phage-specific FDA guidance, so developers use general biologics frameworks. Today nearly all treatment happens under emergency / single-patient expanded-access INDs — the pathway that treated the landmark 2016 Patterson case and seeded IPATH.

The Belgian model

Since 2018, Belgium regulates phages as active ingredients of magistral preparations — compounded per individual prescription, with quality certified by Sciensano. It is the most pragmatic working framework in the world and the reason Belgium is a clinical phage hub.

Regulatory FAQ

Is phage therapy FDA-approved?
No. As of 2026 there is no FDA- or EMA-approved bacteriophage therapeutic marketed as a drug. Phages are regulated as biological products; in the US they fall under CBER (the Center for Biologics Evaluation and Research).
How do patients get phage therapy legally today?
Through clinical trials, or single-patient compassionate use under an FDA emergency Investigational New Drug (eIND) authorization in the US, or national named-patient frameworks in Europe — most notably Belgium’s "magistral" preparation system, where a pharmacist compounds a phage preparation to a physician’s prescription.
What is the European Pharmacopoeia chapter 5.31?
A general chapter (published 2024) setting minimum production and quality requirements for phage therapy medicinal products — including the personalized/"adapted" product. It is the first formal pharmacopoeial standard for therapeutic phages and is non-binding but widely referenced.
Why is a phage cocktail hard to approve?
The conventional drug paradigm assumes a single, fixed, unchanging molecule. A personalized or adaptive phage cocktail — where strains are swapped to match a patient’s isolate — does not fit that model. Resolving this (e.g., via "platform technology" frameworks) is the field’s central regulatory challenge.
See the trials in progress →The roadmap to market
Scientific & educational content. As of 2026 no bacteriophage therapeutic is approved as a marketed drug in the United States or European Union. Phage therapy is available only through clinical trials, compassionate-use / expanded-access pathways, and national magistral frameworks. Nothing here is medical advice or an offer to sell a therapeutic.